Literature DB >> 12727443

Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation.

Frédéric A Meunier1, Godfrey Lisk, Dorothea Sesardic, J Oliver Dolly.   

Abstract

Nerve sprouts emerge from motor nerve terminals following blockade of exo-endocytosis for more than 3 days by botulinum neurotoxin (BoNT), and form functional synapses, albeit temporary. Upon restoration of synaptic activity to the parent terminal 7 and 90 days after exposure to BoNT/F or A respectively, a concomitant retraction of the outgrowths was observed. BoNT/E caused short-term neuroparalysis, and dramatically accelerated the recovery of BoNT/A-paralyzed muscle by further truncation of SNAP-25 and its replenishment with functional full-length SNARE. The removal of 9 C-terminal residues from SNAP-25 by BoNT/A leads to persistence of the inhibitory product due to the formation of a nonproductive SNARE complex(es) at release sites, whereas deletion of a further 17 amino acids permits replenishment and a speedy recovery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727443     DOI: 10.1016/s1044-7431(02)00016-7

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  39 in total

1.  Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism.

Authors:  Callista B Harper; Sally Martin; Tam H Nguyen; Shari J Daniels; Nickolas A Lavidis; Michel R Popoff; Gordana Hadzic; Anna Mariana; Ngoc Chau; Adam McCluskey; Phillip J Robinson; Frederic A Meunier
Journal:  J Biol Chem       Date:  2011-08-05       Impact factor: 5.157

Review 2.  Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.

Authors:  Ammar Nassri; Zeeshan Ramzan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

3.  A molecular basis underlying differences in the toxicity of botulinum serotypes A and E.

Authors:  Mark Bajohrs; Colin Rickman; Thomas Binz; Bazbek Davletov
Journal:  EMBO Rep       Date:  2004-11       Impact factor: 8.807

Review 4.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

Authors:  B R Singh
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 5.  The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.

Authors:  Sergio Pantano; Cesare Montecucco
Journal:  Cell Mol Life Sci       Date:  2013-06-11       Impact factor: 9.261

Review 6.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

Review 7.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

8.  Neuronal delivery of antibodies has therapeutic effects in animal models of botulism.

Authors:  Patrick M McNutt; Edwin J Vazquez-Cintron; Luis Tenezaca; Celinia A Ondeck; Kyle E Kelly; Mark Mangkhalakhili; James B Machamer; Christopher A Angeles; Elliot J Glotfelty; Jaclyn Cika; Cesar H Benjumea; Justin T Whitfield; Philip A Band; Charles B Shoemaker; Konstantin Ichtchenko
Journal:  Sci Transl Med       Date:  2021-01-06       Impact factor: 17.956

Review 9.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

10.  Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency.

Authors:  Steven C Cardinale; Michelle M Butler; Gordon Ruthel; Jonathan E Nuss; Laura M Wanner; Bing Li; Ramdas Pai; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Botulinum J       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.